BACKGROUND: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolving.
Rationalisation of treatment requires identification of those patients more likely to benefit from a particular therapy. We reviewed the outcome of patients treated with abiraterone at our Institution to describe factors predictive for response.
PATIENTS AND METHODS: Patients with CRCP treated with abiraterone were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included overall survival (OS), prostate-specific antigen (PSA) response and time to PSA progression (TTPP). The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival data.
RESULTS: A total of 61 patients met the inclusion criteria. In multivariate analysis, three independent predictors of OS were identified: Duration of response to androgen deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p≤ 0.001).
CONCLUSION: This study has identified three factors predictive for response to abiraterone in CRPC. Duration of response to ADT has not been previously shown to be a predictive factor for patients with CRCP. We suggest that a prospective validation is required.
Written by:
Afshar M, Al-Alloosh F, Pirrie S, Rowan C, James ND, Porfiri E. Are you the author?
Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K; School of Cancer Sciences, University of Birmingham, Birmingham, U.K; Cancer Research Centre, University of Warwick, Warwick, U.K.
Reference: Anticancer Res. 2015 Feb;35(2):1057-63.
PubMed Abstract
PMID: 25667494